Association of serum sclerostin and osteoprotegerin levels with the presence, severity and prognosis in patients with acute myocardial infarction
- PMID: 35546224
- PMCID: PMC9092859
- DOI: 10.1186/s12872-022-02654-1
Association of serum sclerostin and osteoprotegerin levels with the presence, severity and prognosis in patients with acute myocardial infarction
Abstract
Background: Bone-related proteins (such as sclerostin and osteoprotegerin [OPG]) are involved in the development of atherosclerosis. However, the relationship between bone-related proteins and acute myocardial infarction (AMI) has not been extensively evaluated. The purpose of this study was to assess the association of serum sclerostin and OPG with the presence, severity and prognosis in patients with AMI.
Methods: This study prospectively enrolled 152 patients attacked by acute chest pain. Serum sclerostin and OPG were detected within the first 24 h after AMI diagnosis by ELISA kits. The AMI predictive efficacy of sclerostin and OPG were analyzed by receiver operating characteristics (ROC) curve. Univariable and multivariable linear regression analyses were performed to determine the association between bone-related proteins and scores indicating the severity of coronary artery occlusion. Moreover, prognostic values were assessed by Kaplan-Meier curves and Cox regression analysis.
Results: There were 92 patients in AMI group, 60 in non-AMI group. Serum levels of sclerostin and OPG were significantly higher in AMI group than in non-AMI group (all p < 0.001), which showed predictive value for the presence of AMI (all p < 0.001). The area under the ROC curve values of sclerostin and OPG were 0.744 and 0.897, respectively. A multivariable linear regression analysis demonstrated that Ln-transformed sclerostin (β = 0.288, p = 0.009) and Ln-transformed OPG (Ln-OPG: β = 0.295, p = 0.019) levels were associated with GENISINI score, independently of conventional clinical parameters. In addition, Ln-OPG levels were still positively associated with GRACE score after adjustments (β = 0.320, p = 0.001). During a 1-year follow-up, patients above the median of sclerostin levels had higher incidence of major adverse cardiac events (MACE) than those below the median (p = 0.028). It was also observed that the MACE rates were higher in patients above the median of OPG levels, though no statistic importance (p = 0.060). After adjusting conventional risk factors by multivariate Cox regression, Ln-OPG was associated with incident MACE (hazard ratio = 2.188 [95% confidence intervals 1.102-4.344], p = 0.025).
Conclusions: Bone-related proteins could exert a potential role in early risk stratification and prognosis assessment in patients with AMI.
Keywords: Acute myocardial infarction; Atherosclerosis; Osteoprotegerin; Prognosis; Sclerostin.
© 2022. The Author(s).
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
Similar articles
-
Osteoprotegerin in ST-elevation myocardial infarction: prognostic impact and association with markers of myocardial damage by magnetic resonance imaging.Int J Cardiol. 2013 Sep 1;167(5):2134-9. doi: 10.1016/j.ijcard.2012.05.101. Epub 2012 Jun 15. Int J Cardiol. 2013. PMID: 22704876 Clinical Trial.
-
Sclerostin and osteoprotegerin: new markers of chronic kidney disease mediated mineral and bone disease in children.J Pediatr Endocrinol Metab. 2020 Nov 26;33(11):1383-1390. doi: 10.1515/jpem-2020-0140. J Pediatr Endocrinol Metab. 2020. PMID: 33068383
-
The Value of Combined Detection of Serum BNP, Cardiac Troponin-I and Dynamic Electrocardiogram in Early Clinical Diagnosis and Prognosis of Patients with Acute Myocardial Infarction.Discov Med. 2024 Mar;36(182):598-603. doi: 10.24976/Discov.Med.202436182.56. Discov Med. 2024. PMID: 38531800
-
Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications.Nephrol Dial Transplant. 2015 Aug;30(8):1345-56. doi: 10.1093/ndt/gfv081. Epub 2015 Apr 7. Nephrol Dial Transplant. 2015. PMID: 25854266 Review.
-
From Classic to Modern Prognostic Biomarkers in Patients with Acute Myocardial Infarction.Int J Mol Sci. 2022 Aug 15;23(16):9168. doi: 10.3390/ijms23169168. Int J Mol Sci. 2022. PMID: 36012430 Free PMC article. Review.
Cited by
-
Correlation between osteoprotegerin and coronary artery calcification in diabetic subjects: a systematic review of observational studies.BMC Cardiovasc Disord. 2023 Feb 21;23(1):96. doi: 10.1186/s12872-023-03123-z. BMC Cardiovasc Disord. 2023. PMID: 36809976 Free PMC article.
-
Differential gene expression patterns in ST-elevation Myocardial Infarction and Non-ST-elevation Myocardial Infarction.Sci Rep. 2024 Feb 10;14(1):3424. doi: 10.1038/s41598-024-54086-w. Sci Rep. 2024. PMID: 38341440 Free PMC article.
-
Causal effects for genetic variants of osteoprotegerin on the risk of acute myocardial infarction and coronary heart disease: A two-sample Mendelian randomization study.Front Cardiovasc Med. 2023 Mar 7;10:1041231. doi: 10.3389/fcvm.2023.1041231. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 36960470 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases